EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

The metabolic escape: how tumor metabolic reprogramming drives drug resistance

Yan Chen, Zixu Wu, Wenzhe Si, Xujun Liu

PeerJ · 08.06.2026 · 14 · e21400

DOI: 10.7717/peerj.21400 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift PeerJ, online erschienen am 08.06.2026. Verfasst von Yan Chen und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Laboratory Medicine, Peking University First Hospital, Beijing, China. Hauptthemen laut MEDLINE: Drug Resistance, Neoplasm, Metabolic Reprogramming, Neoplasms. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 90 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Natural Science Foundation of China, Beijing Nova Program, Beijing Natural Science Foundation.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

In the last few years, metabolic reprogramming has been recognized as a fundamental characteristic of cancer, and is also acknowledged as a crucial cause to drug resistance, which consistently acts as a significant barrier in cancer treatment by allowing tumor cells to adapt and escape various therapies. This review gives a systematically investigation of how metabolic reprogramming contributes to drug resistance in cancer, including aerobic glycolysis (also known as the Warburg effect), lactate metabolism, glutamine addiction, lipid synthesis reprogramming, mitochondrial and ion metabolic changes. Furthermore, by clarifying the mechanisms behind these reprogrammed metabolic pathways, we explain how these changes lead to drug resistance and highlight potential molecular targets for therapeutic intervention. Additionally, we discuss emerging strategies aimed at exploiting these metabolic vulnerabilities, offering new insights for overcoming drug resistance in cancer. By integrating recent discoveries in this field, we present a unified perspective on targeting metabolic vulnerabilities to overcome drug resistance, which is an urgent need in precision oncology, and timely and concise insights for cancer biologists and researchers in the field of exploring the metabolic mechanisms of drug resistance. We hope this review will provide valuable insights for molecular tumor biologists seeking to elucidate the molecular roles of tumor metabolic reprogramming and drug resistance in cancer.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Drug Resistance, NeoplasmMetabolic ReprogrammingNeoplasmsHumansAnimalsTumor MicroenvironmentAntineoplastic AgentsGlycolysisMitochondriaWarburg Effect, Oncologic

Stichwörter der Autor:innen

CancerCancer therapeuticsDrug resistanceMetabolic reprogrammingTumor microenvironment

Substanzen

Antineoplastic Agents

Autor:innen und Institutionen

  • Department of Laboratory Medicine, Peking University First Hospital, Beijing, China.
  • Department of Laboratory Medicine, State Key Laboratory of Vascular Homeostasis and Remodeling, Peking University Third Hospital, Beijing, China.

Förderung

  • National Natural Science Foundation of China
  • Beijing Nova Program
  • Beijing Natural Science Foundation
  • Key Clinical Projects of Peking University Third Hospital
  • Peking University Third Hospital Fund for Interdisciplinary Research

Zitieren

APA

Chen, Y., Wu, Z., Si, W., & Liu, X. (2026). The metabolic escape: how tumor metabolic reprogramming drives drug resistance. PeerJ, 14, e21400. https://doi.org/10.7717/peerj.21400

Vancouver

Chen Y, Wu Z, Si W, Liu X. The metabolic escape: how tumor metabolic reprogramming drives drug resistance. PeerJ. 2026;14:e21400. doi:10.7717/peerj.21400

BibTeX
@article{Chen2026,
  author = {Chen, Yan and Wu, Zixu and Si, Wenzhe and Liu, Xujun},
  title = {The metabolic escape: how tumor metabolic reprogramming drives drug resistance},
  journal = {PeerJ},
  year = {2026},
  volume = {14},
  pages = {e21400},
  doi = {10.7717/peerj.21400}
}
Infokarte | EUVIMED

Artikeldaten derzeit nicht verfügbar.

Recherche